Article Text

PDF
THU0212 Tumor Necrosis Factor α Inhibition in Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthritis: Treatment Response, Drug Survival and Patient Outcome
  1. J. Corli,
  2. R.-M. Flipo,
  3. P. Philippe,
  4. A. Bera-Louville,
  5. C. Wibaux,
  6. J. Paccou
  1. Département de Rhumatologie, CHRU de Lille, Lille, France

Abstract

Background Several studies have demonstrated that TNFi are efficient in non-radiographic axial spondyloarthritis (Nr-AxSpA). Intriguingly, few investigations have directly compared ankylosing spondylitis (AS) patients with Nr-AxSpA patients, and fewer still have compared rates of response to first line TNFi treatment.

Objectives The purpose of this study, which involved a tertiary care cohort, was to (i) evaluate baseline characteristics of Nr-AxSpA and AS treated by TNFi; (ii) assess the response to first-line TNFi treatment; (iii) compare drug-survival duration and rates.

Methods Inclusion criteria were patients with axial SpA who initiated first-line TNFi treatment between April 2001 and July 2014 and were followed up for at least 3 months. Efficacy criteria were an improvement of at least 2 points (on a 0 – 10 scale) or a 50% improvement in BASDAI. Baseline characteristics, responses at 12 months, and drug survival were compared between AS and Nr-AxSpA.

Results A total of 361 patients were included in the study (AS: n=263; Nr-AxSpA: n=98). AS patients were more often male (65.02% vs. 45.92%; p=0.001) and had longer symptom durations (11.71±9.52 vs. 7.34±9.30; p<0.001). Median levels of acute-phase reactants (CRP and ESR) were significantly higher in AS patients (p<0.001 for both). Median BASDAI scores at first line TNFi initiation were not higher in Nr-AxSpA patients than in AS patients (59 [49-70] vs. 60 [50-70]; p=0.73). BASDAI 20 and BASDAI 50 response rates at 12 months were not statistically different between AS patients and Nr-AxSpA patients (74.58% vs. 64.58%; p=0.19 and 61.02% vs. 50.00%; p=0.19 respectively). No statistically significant difference in terms of survival was observed between AS and Nr-AxSpA patients (p=1.00).

Conclusions Treatment response, drug survival and patient outcome in our study were similar in patients with AS and Nr-AxSpA after first line TNFi initiation.

References

  1. Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, et al. Tumor necrosis factor-alpha inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013;65:3096-106.

  2. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815-22.

  3. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012;64:1415–22.

Disclosure of Interest J. Corli Grant/research support from: Pfizer, R.-M. Flipo Grant/research support from: Pfizer, P. Philippe: None declared, A. Bera-Louville: None declared, C. Wibaux: None declared, J. Paccou Grant/research support from: Pfizer

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.